You misspelled clueless

link to apply

careers.sgim.org/job/academic...

Agree for commercial insurance or Medicare

Too expensive within Medicaid

If there is one clinical driver of practice and it's not accounted for in any analysis I can't in any confidence trust the observational comparative effectiveness

Other than the rate of ODS is very very low which is most important part of evidence base

No, it does

It's just pseudo random but may correlate with other practice patterns and serve as a marker

FWIW I do fast correction for most

And if they live in low 120s from chronic badness I don't bother fixing it unless underlying issues fixable

Remains the sole clinical driver of speed

Rest is practice variation

Can't omit it and trust evidence at all

None of these adjust for chronicity

It's the major confounded here between an acute episodic thing vs chronic badness

Copied from my Twitter thread:

NOW WHAT?

removing restrictions would improve access w/o step therapy (which makes no sense here) or prior auth

But $$$ is a real concern

Here is our pitch why may be less of an issue in Medicaid

AND

Restricting DPP4i instead of GLP/SGLT can offset some costs

This was inspired by an amazing study that I did a very popular Twitter thread on

x.com/AnilMakam/st...